Fulcrum Therapeutics
NEWS
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look.
The month of February ended with a flurry of clinical trial announcements. Here’s a look.
Pharma and biotech companies bolster their executive leadership teams and boards of directors with this week’s appointments.
On Monday, the two companies forged a collaboration and license agreement that has the potential to be worth more than $450 million.
Data presented in an oral presentation at World Muscle Society meeting highlighted safety, tolerability, pharmacokinetics and target engagement of losmapimod in patients with facioscapulohumeral dystrophy.
Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.
Cambridge, Mass.-based Fulcrum Therapeutics just acquired a worldwide license with GlaxoSmithKline (GSK) to develop and commercialize losmapimod.
JOBS
IN THE PRESS